Table 3.
Multivariate analysis.
HR | SE | 95% CI | p value | |
---|---|---|---|---|
EFS | ||||
Age at allo-SCT | ||||
<14years | Reference | |||
>=14years | 0.84 | 0.45 | Jan-58 | n.s. |
Gender | ||||
Male | Reference | |||
Female | 1.18 | 0.68 | 2.06 | n.s. |
Graft Type | ||||
HLA matched | Reference | |||
HLA mismatched | 0.84 | 0.45 | 1.58 | n.s. |
Disease Stage at allo-SCT | ||||
RD | Reference | |||
CR | 0.4 | 0.20 | 0.77 | 0.01 |
OS | ||||
Age at allo-SCT | Reference | |||
0.76 | 0.42 | Jan-36 | n.s. | |
Gender | ||||
Male | Reference | |||
Female | 1.31 | 0.74 | 2.31 | n.s. |
Graft Type | ||||
HLA matched | Reference | |||
HLA mismatched | 0.76 | 0.41 | 1.39 | n.s. |
Disease Stage at allo-SCT | ||||
RD | Reference | |||
CR | 0.29 | 0.15 | 0.57 | <0.01 |
EFS event free survival, OS overall survival, DOD death of disease, HR, hazard ratio, SE standard error, CI confidence Interval, RD residual disease, CR complete remission, allo-SCT allogeneic stem cell transplantation, n.s. not significant.